Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depression
作者:Bruce A. Dressman、Eric G. Tromiczak、Mark D. Chappell、Allie E. Tripp、Steven J. Quimby、Tatiana Vetman、Adam M. Fivush、James Matt、Carlos Jaramillo、Renhua Li、Albert Khilevich、Maria-Jesus Blanco、Stephon C. Smith、Mercedes Carpintero、José Eugenio de Diego、Mario Barberis、Susana García-Cerrada、José F. Soriano、Jeffrey M. Schkeryantz、Jeffrey M. Witkin、Keith A. Wafford、Wesley Seidel、Thomas Britton、Carl D. Overshiner、Xia Li、Xu-Shan Wang、Beverly A. Heinz、John T. Catlow、Steven Swanson、David Bedwell、Paul L. Ornstein、Charles H. Mitch
DOI:10.1016/j.bmcl.2016.10.067
日期:2016.12
hold promise as novel therapeutic agents for the treatment of major depressive disorder. Herein we describe our efforts to prepare and optimize a series of conformationally constrained 3,4-disubstituted bicyclo[3.1.0]hexane glutamic acid analogs as orthosteric (glutamate site) mGlu2/3 receptor antagonists. This work led to the discovery of a highly potent and efficacious tool compound 18 (hmGlu2 IC50
代谢型谷氨酸2和3受体的负调节剂在动物模型中显示出抗抑郁样活性,并有望作为治疗主要抑郁症的新型治疗剂。本文中,我们描述了我们准备和优化一系列构象受限的3,4-二取代双环[3.1.0]己烷谷氨酸类似物作为正构(谷氨酸位点)mGlu2 / 3受体拮抗剂的努力。这项工作导致发现了一种高效且有效的工具化合物18(hmGlu2 IC50为46±14.2nM,hmGlu3 IC50 = 46.1±36.2nM)。化合物18在小鼠强制游泳试验中以1mg / kg ip的最小有效剂量(MED)表现出活性。在大鼠脑电图研究中,它在3和10mg / kg ip ip时显示出促醒作用,对运动活性没有任何显着影响。